MPA

HPV AND ANAL
ED
CEMBER 2
RefqrqnL* and mminis1rnti￿ Detslls
Roport of the Trustees
2-17
llnde￿ndent Examlners, report
18
Stat¢nxrt of An•￿1•1 AIX1v￿
19
B•l•nce Sheet
20
Ststsment of Cash Flow
Notes to the Flnandbl Statemnts
22-29

FOR THE YEAR
EMBER 2
Reference and Admlnlstratlve Detslls For the Year ended 31 December 2023
LEGAL AND ADMINISTRAllVE INFORMATION
TRUSTEES
C Ajmada
J Alm&Ja
T Amada
REGisfERED OFFIC
128 fjty Road
London
ECIV 2NX
REGISTERED COMPANY
NUMBER
07955451 (EnglarKI arKI Wales)
REGJsfERED CHARITY
NUMBER
1147457
INDEPENDEKr
EXAMINER
Knox Crcpr*r LLP
65 Leadenhall Street
LoTrJon
EC3A 2AD
sOUc￿oRs
Strjne Klng
16 St John's La
London
ECIM 48S
BANKERS
16 KlrKJ Street Covent Garden
London
WC2E 8JF

EHPV
NCER F
UND
qi
The and Anal CarKer Fourmlation Linwtuj ￿ a UINtsJ ￿ngd￿ (UK) subsdiary of Tr HPV and Anal Can￿r
FcyJndatM in the Unrted Ststes of ATr*rica lu￿) Ictsrity EIN: 27-3217520). whth e5tstAshed April 2010. AII
work undertaken by the UK FoJ￿jat10n is in CollabJratiC￿ WTth Its parenL
The HW and Anal QirKer Foundavon Llmtted bs a chbrltsNe ccrfnpany by shales. Inc￿)Drated In the UK on
the 20th February 2012 and regi#ereO os a thJrlty on the 25th May 2012. The company was estsNisF*d through its
Articks of Ksswtytion, establshed d)ierts and Fth¥*S (* Il* dwrtiaL4e C￿pany. stsres in the cornpany
re by The HFV Anal ca￿ in LIS4.
The HPV al￿ Anal Cart8 F0uTrjat￿ board (C￿s1￿5 of f￿r [r￿mberS. The direc￿ are re$r#)￿'b￿ for the kgal,
flnandali pr￿raM and rn￿ager￿t o¥wlght of ￿ tharlty. The Iwrd hdd hs ￿nL￿1 meeting on December 28, The
dally respCfiSl￿1knes and mtssknn of tr* Foundatkn are by the teams In the and ￿ UK. In the btter,
the Dlrertor of irL OpttatioN4 ts re¥￿n¥t￿e the coorflnbtron ￿ thy.ttrday
Vlhen tr* Trusteu advertlse fty nthy b)3rd ff*mbws, C¥KlhYates art 9￿￿¢•j the gwal wblL A dlverse mlx
of ￿lIS and baCkgr￿TrY$ a￿ PrtyFertr¥e trL&ees are Intwmthved wor tt* apOntsnenL As part ol t￿r
inducbon, new trustees are an of the of The HFV *mal Catxtr Foundaikni In addbtron to
COF4e5 of the onJanlzatlon'5 flnandal dc￿rI￿nts, Waw* aThJ PK4ldes.
RI￿ Management
The trustees of the Foundation hcld the reSF¢)ns¢￿1tty of safegu?￿l￿g the dwrws assets ar￿ are sa￿￿1ed that
sterrfj are kn place to I￿￿9)te tIM)5e rbks ¥yNch thartty w f￿.
Itls Inwrtant to note ￿t the parert and sjbthy org*Wzatkns cptrate a5 crf* enljty In athWThJ the mlssth of
Ihe or9anisatlon. The rtvenue for the charity is dependent ¢k)natkns from tr* put4￿. Income for the UK HFV ènd
Anal CarTh Ftyjndailon In 2023 was £579,781 aThJ expeth4thre was £342,973.
Total free re5erve5 at year affKJJnbJ to E281,655.
Tru*ees have the arnujnt ol re5erve5 it regaTds as a mlnlmum pntht wuirwnent. Tly have
conduded that provision for three Lwernts"rvJ YeseNes that enable the wjanisation to meet ts finanoal
commitsnerts induding grants, contracts aNS staff sakries is suffioenL Ths ￿1)Uld alkm time to manage cost
re￿ctionS ty generate ftw)ds as reWI￿d whi￿¢ minimisirvj ￿ impact M service prtyi5￿. At 31 Decgnter 2023 tli5
amwnled lo £21,478. This indiotes a heathy swplus c+ free restr*s of £260,177, whkh will be allo(ated for use In
2024 and 2025 to 5YPP(rt C￿r initiatives to anwM*r anal (Jrttr pthits, and Kcelerate pYevenlkJn and research
methods that dimlnate human Pa￿lI)Ma￿￿jS, and ar¥91

RE
RT
EES
2023
Publlc Benefft
The tru*ees referred to the guklan￿ ¢￿taIn￿l in the (hwity cc￿55￿ 5 gufjdar￿ on put1￿ benefit
when reweéding the chanvs alrrs atid obJettNes and in plam.ng ffijtu￿ a(livitie>
Hlstory
The Fwndation was fltst estsb114￿ in the USA In 2010 ty three slbllr4¥ who h)st thdr mother, aged 53, to 5ta9e IV
HPV-related anal uFKer. Frvstrated by the tknpwtk arKI cL¥nmunty supt*>t avallabk to ￿, they ueated
the or9ani5atK)n lo fill the vold QLWY by scant w￿1(. soentific and medKal foajs on this disease and tt5 cause.
human papbllomavlrus {HPV}. HPV owes anal Ca￿er aThJ at *ast fNe cthw oKers, ar￿Un￿￿j to 5% of cancws
worldwlde. T1￿ cancers prwentsble. In 2012, the or9￿1zAtion expgrKled to the UK wth 2013 as Its flr# fLII
oPera￿onal year.
Mltslon
The HPV a￿1 Nnal C)rw FJJndatl)n em1￿ anal •TrJ accdwates preven￿Oft and resea
methr)Js that ellmlrote anal caw and the ￿ruS that ouses tre cases, HPrf.
HlghfKJht tre el human paplM(rnirus (HFV) kn contIa￿ ranw;
Advor4te for prevenvon metros that wll and HPV.thted oncers, lThJuthng geThjer.￿Utr￿l
vaccination..
e￿rnte a ￿re Ic* the 5% cl al lthat are catsed bi HPV. wlth • on anal onw,. and
The Ne•d
A ThJndan￿ts1 obJe¢tyve of Foundatlons Is to retse the of anal carKer and 0￿r HPV.rekted
can￿r$. HFV Is a cL4nmon 5kJn vlnjs that nearty every sexualty a¢iive perg)n will get at 5cffie point in thefjr lfve
rpv affeils Èoth men and and is wit4e (ty 5% oftt* wc4hJ's can￿r HPV causes of the
anus. ceNx, Iwd and nrt perms, vagina, axl vtha.
Protectlon against HFV through un￿1 HPV vac(Inati¢￿ is a CTltical putjlt health gcol. Wth HPV IdtrbtKled as a cause
ofgx differenttypes ofcancer, a￿1 5% 01 cancer cases *tyl¢tsid¢ rc ￿ kn￿rat￿ethat we wotecttheentire popuktion
agalnst ￿. Tr* eff￿t￿ to red￿e relatsd to HIW Is to wevent [nI￿al infection of the wrus
through IrnmunLsatIc￿. The F￿jndatIc￿ atl￿e¥e$ thi5 impKrtant alm thwjh ts thrts to a(fvan￿ equal access to HPV
otectKm for t*Jth W at¥1 glrls thrcwgh geThJeI-￿utraI vaconation agai￿t the ￿rus. At the Intrc¢Juthon d the
v7ccirye in most ￿ntr￿ orty girls were abte to receve this lrfe.$a￿ry irtervention were generalty
exclL*J8J. The crea￿1 [￿j the cc631ilknrs n the US UK to erwre all thIld￿n have equal auess to
prot￿tion agalnst these eanc*5. The US the rnIle*￿ of re{￿n￿￿'r￿j HPV protect￿ to all thI￿re￿ in
2011. Follow*￿ the FoundatK)n sffte-yearthcacy camF*n In the sclKd4)asgJ HPV vaccinatKJn for iw began
In SeErt￿ntser 2019. C￿r frKus ts the sa￿* wottttiin for a5 wel as girls auv55 Eurcyei and

023
ntin
Whlle we work to prevent fubjre cases. it is also fvTrJornentsl that scierfjfic aThJ rnedical thsparTiies are addressed fc
the populai*Jn that will contlryje to be dwjncsed WTth HPV-reL*ed crn Ilke anal Canw. Treatment options have
barely progressed 51rtt the 19705 aThJ minlmal researth has uThlertaken in new therdP￿s. The m￿￿31 and
nt￿¢ communltb researth trds and mNest￿ in rThel *leas to a cure.
The stigma sur[￿rI1￿j •rnl oarKer rewo1￿ one of the centsBI d￿1￿5 to Improving ￿jt(Qrnes fv anal c3rKer
patients. UnfC¥tUnJts￿, many medKal centres ￿de Ilmtted infmDon spedft to the ex¢erience ￿ anal
cancer. Many patients feel isohitoj and Jack the supF#)rt arKI ebJoUc￿l resource5 that signifv3nUy improve quallty
of lrfe durtng and after treatmenL
Strategl•s to Achl•ve Our Go•L•
We ath￿ve c￿r mIs￿L￿ kn the UK and US fhrwh collabcrfation *ith scientits, dinwns, wr￿T$, oryan15jts.o￿, and
government agendes,. e{lucatk￿ ￿ stskekJkJers and the general publK; survlvcf 51PPrt and Investment In the
m&Jlcal and Saentir￿ community to eNJ HPV and the CaLW. SFedflcOl￿. we take aojon to destigmat
nd ralse awareness attywt HPV, HPV.related cancws and anal C￿￿. lThyease acces5 to the vacdne; lrnprove
xreenlng wotocols and care,. empov& anal can￿r thrlvejs: and xtelerate a cwe for anal can￿r aTrJ
otr*r HPV.relJted Illnes
MOMAN Is •n l•l￿d. R•e• to End HPV
The Nom￿ CaryakJn rnLse5 aware1￿ atoJt tre HPI.relèted cancer epwjemk In men and and educates
atrp)Ut tJ)e impJrtarKe of ￿￿ersal HFV vxdnaYcA), challerrfJirvJ participants to theme endurance races auoss
the worfd. It is thrwgh suth extreme of atNethJsm thot NOMEN h)nour the stru99le and Isolaoon that many
ncer Pat￿nts led.
N014AN has teen an hicredlbty s(Kcesslul ompahjn. SrKe its Ir¥3wJwal t￿rt In 2013 wlth the Barcelona - Iblza.. R¢)w
to End HFW. ovw 200 Indi￿¢￿15 - arnl thelr hundrèts of gJPF¢rttss - have erftsxed the cause our vaknes.
These NOMEN h)ve raised thwarw￿ ab¢xrt HP4 crn on a kxal, national intemational scak, as wdl as fvnds
to sukyjrt our pr¢￿r￿me5.
2023 was a spedal year the I￿nda￿On as ts 10th annhErsary of the No￿ ornpa￿n. Book*ndiry our event
raleThJar, NOMAN rpders tr#Jk on the Haute R(￿ events at Crans-montsna and Ventwx. The Haute Route 15 the
worfd'5 rTrJ5t pre51igious cydkn9 event fty amatwr cydists. Tr r&t5 unparallded experien￿ 3-,5.arKI
7. day professional road everts in the most kork qdlrbJ (lesritkitions wcffldwKbe. ￿rIr￿j the 3-day events,
rlders tske on s<￿e 3C(lkni and KKJckn+ of ¥ErtOcal ascen( testir¥J I￿nselveS agaknst the most irfamous dlmbs In
the wld. all In the name of wa￿1ng awareness of HPV-rektèJ Car￿5. Ald1t￿namVI at each tvent all p3rtldpants,
{nearty 3000 parIkI￿nts In toial) are given ￿r END Htry socks to16ght LP the aThJ generate (onversaikjn atojt
(￿r work to dSmlnate HPV ￿￿r5. ctrfwnder Trlstrn fvJm)da also spoke wr ml&sion to dlrninate HPV
cancws at the wslage br￿.

July saw the ItAh anr4veYsary ethtKm of tr* BarcelDna.IExza'. Rth¥ to ETrJ HFV, wr flagshlp event. NOMAN'S O￿n
rowlng race pts teams of amatwr rowers agalA4 each other in a three-day wint mss the med￿eTronearn. Rowing
across an o￿n Ls like no othw 5tort: it is as nxjth atout the crtsv5' atmlty to cope ￿￿ntalty as f( is ab￿rt techn￿Ue
and physcal strength. The race has seen great interest amw adventwe seekws, and n)wers rarKJe freffl people wth
p￿or expertence to ffl0￿ Seaso￿ rovts5 k¢knng to attwnrt an cKean row before commttvng to a knryer chalkn9e
suth ¥$ the Padfk fx Adantk
2023 sèw great Interest from (￿r commlmlty, a￿1 the rrtum IA partlctsnts from lco￿ng to be part
of thts speaal anniversary ra￿, akjngsde supwrters of OUT V•YJtk Thty Jolwj on water by Olympk
gold medallsr, Will Satth MBE as our WX4AN afflba￿dCf wh)se partiapation 9EwabJ inueased Intsrest 8nd
supwjrt for OLK cause.
We are grntefvl for thè 9ew05ty of ￿ Trafyur3 Fourbjatkn fty 5UPP)rt of our campatqn and the
FouTrdatkn's work In 2023 In the lonn of a mètching ContrI￿on of $150.000.
We knk fcfft¥ard to ￿￿￿lIng on Inlttab*s In tr* cThi*vJ year&
In 2018 and 2019 the FcNJndaYon wasinvolved In dIscuss*￿5 to estsNtsh an a(kncy campahJn In Europe to 5ntrodu
gender.rwtral vxonatth across the rewn )Id ccmp• eh'rrinate HPrfarelaW disease5.
VMAN has partnered with the EuroFean can￿ OrwfrsallLN) (ECO} to athlpAe th15 mlsskn. ECO ¥¥ts￿5 trs red
the burden of canw and irnprove wtcomes quallty of care for pthnts through mu￿d￿(lpl1rtary Inltkti*s.
As the Eurcpean n￿40r"￿￿tt tsJpJaYon oryantsaticns woth'rvj In (aw, they convene oncc4ogv
prOf￿￿)nal and pat*nts to a9ree cffl wky. for pc&bve d￿ngel and be the united voKe of the Euiopean
can￿r communlty.
Tojether wlth ECO. the FoundatOM k)oks forward to %4rrkJNJ ELwcwn PDW makef5 to eTrJ the sufferlr¥J caused
by HPV can￿r$. In 2021. we achi￿ed a major Thltstor* by seoJrlrKJ for the first b"me, a commttn*nt to efimlnate
HPV Can￿rS in EuroFes Beatlng CarKer Flan. The HPV Adjcffl Netsvcrt has built on this m)ior success With the
folowing ach￿ In 2023, I￿lu￿n9 sUW>Orting Coun￿ that I￿ fallThJ behlTrJ.
Publlcatlon of the 2r￿ •dltkn olth• HPV Polky Pr•v•nlkn Ad•$
On 22 June. 2023, the HFV Pr￿￿On Pc41q Atlas wa5 at the Rmrlan Parllam&L Thls latest upJate of
the Atlas, In￿lalty published in 2020. led by the European Palllan￿tsry Fcrum for Sexual Ra)r0d￿tiVe ￿.ghts
IEPF) scores 48 European gov￿Ments on thelr approxh to HFV Wev￿￿on - prfmary preventK)n {vaconab'on),
condary prevention (screenlng), arnl Infrntp)n. The tojl akns at r￿￿d1Thj w>.trtrdate put4kly awdiL4ble
informatron across am counlthes of VI￿} Eurcpean regle￿ In li￿ wth WHO ceTvKal cancer ellm1rwtw￿ strategy and
ELTrrope's Pe3￿ng Canw Plan. The 2" eifrt*)n hKJhlvJtrts the geoJrnphicJl disparltks whKh exlst in HFV PreVent￿n
s acrc6s the WHO E￿Opean re9￿, as Ngh1l￿ted ty the ¥￿b* Ea5t-West thde In EPF'S so)res acr055 the
continent.

The Atkis serv&s as a P￿￿1 to actkn.. undethrMrNJ t￿ wl for actjon to tse&Je HPV, in particiAar Ma pollcies
related to HW immuNsatr)n, ceNcal SryEenw aw*J onlire information, and urklerlines the knwrtance of
IMplemen￿n9 the gcois c* Europes Bthting Caw ikn.
OLrt of 48 ￿ntr￿S in 9et*Jraphiol Ewq)e.'
39 countrles183%) offer a naUonal wwan¥ne.
30 courtrfes (64%) provlde gen(*r-r*utsal vx¢Jnation.
23 countrles149%1 malntaln an HPV Vacanat•￿ re9tsty.
25 cryjntrles (53%) e•sy40.fiThJ. g¢wtsrWnert.￿ted ￿lteS wtth gwj or exC&yw￿ irfomatton on HPV
preventlon.
Jn 2023, DenrnarK SweL*n. Flnland, the IK, and Ireknj the tOP-pthfvJ courtries lft HPV preventyon. T
natiorffj have Imr4en￿nted ￿-pr)c￿ Fdw, IndLKfing nauonal routine HPV program5 that are gender.
ulral and fredy a￿dIlable, resulb.ry in h*h vxdnakn rates yJppc*ted ty robu# Immunlsathjn data systems. Tl
akn offer free HPV screenry for addt5 maithn wblic wthtes wtth thai, infomwkn by
ties. Conversety. ctrJntrfes Ilke K0￿0 ￿ Ilerbaij￿ are at of the l&t, marked by a lèck of prfmary
and Sec￿d￿Y preventl)n and an ab5erKe of rellaNe, thIe￿e-based infmtim prevenkn.
The Atlas has been presented at severnl high.levd events through0￿ the ￿r Indi* the Sert4an Parllament, ar
In a presentstkm to senior polltloans aThl Fdkymakers In PoL3nd In Octob¥ 2023.
Launch of HPV &l¢tlon Cro•tl• and Rominl• •nd support for HPV Co•Wtlon, Bulg•rtb
In 2023, the HPV 5UPF¥Xtiry adNw ranv￿n5 on ellmlnatknn In Romanla, Croatki and
B￿garIa to see rnre yoim9 ￿e0￿e Vaccinot￿ against HFV, in with the recThmmend)tlons of EurDpe's Beat￿9
Can￿r pfan, anrj ceThul sCr￿￿r￿j prcty¥ammes e&at41gled in eath cwnty.
Eastem European tt￿rrtrI¢S fall behiTrJ rnany Ot￿ Eurcgean count￿5 In effThts to diminate HPV ¢arKers, w￿h
low ￿1$ of HPV Immun&tb)n CWVKal s¢reenlng. E2th mMth, the HPV ktion nets¥tyk organlses video
ccfifererw brtn9ir#J toJether physkiars, sdentists, put4ic ￿1th ekperts. and rePres￿￿t￿eS of mothers and your
peop￿ from all over the respective countr*s in or(lerto aL*lre5s ￿￿entify￿￿t￿irt￿ immment. In county
Cwrdsnat￿s Ikive teen appointed In 2023 to SUPkhXt the Coalit￿ aThJ thtify a￿35 of need arn1 OPFX)rtunity. At
ECO Surnn￿t in November 2023, wcfk In Romania, Buk)Jwla a￿1 CroalSa wa5 dbujssed at a we(l-attended satell
rnetingi wludlng tsy the Ckwty Health Mith of Bul9aria.
SFeilfic aththnents fvr each ofthe 2023 are dets[l￿ befvyrt.

NC
MrrED
31 DECEMBER 2023
con
Romanla
HPV Acticffi Romanla- {A¢lUr￿ HPI Romanial ￿ WirvJ national organts**)r& and to mobllse and J￿n
forces to irnplement [MJIK￿5 at irKreasing HPV ￿￿C￿n3t￿ffi, s£reenlng and Infom)atlon ¢oveTrge. A wide range
of Orga￿sat￿Ons have come tO9ether as wt of thls new ￿p3￿n, oll to aLtfjcn is ftt￿e￿ on three poirts,.
Rcxbtine gender-neLthI HPV vac(inatKJn fty ap 11-1&￿r￿d$ with gJ% uptske by 2030.
A nati£￿1 w>puLiti0n-￿th cemcal can￿r streeniw kyrwjrdmrne. based ￿ HPV te5Vng and includfjrrfj self.
sampllng as an Ok)tKin fty hard-t￿each grtyJp5 and othw5. with 70% of women screer*J ty the age of 35
nd agaln ￿ age 45, to be by 2030.
A SUStstr￿ pu￿￿ educ3thJn HPV awareness. vacdnatkn ènd s¢JeenlThJ.
In 2023:
In the context cl Wa￿￿ Carur Day (4th FeMwy) a det•te was padIan￿Ortan$ I￿$[n9 the
theme Lrf 'Wc4nen's Ca￿er5 - DITectsirs ICK Improvirvj Pr&*ntion. Early DS&Jnosts, )nd Earfy A￿55 to
Tieatment to Reduce IrK*lerKe aro Improve SuNfval Ratss., In order to Sdentfy publc kealth opp)rtunlttts
to de(Te)se canw InddaKe Imwtye rats Immurisatlon and sueenlng )re key tcKAs In the
PLblK heath tcdklt to &ldre55 IWJ
In Mayi a ￿t￿lC awareness campaw was IwrKhed kn Rclnanian focthll sxadlums, reachlng thousaThJs of
fans wlth our crlucal rnessage dar¥ps of HPV its link to at kasl diffwent types of caKer.
objective of this campalgn 15 to Whten awarene55 and er￿j￿￿ge vacdnavon, in partkular through
encouragirrfJ parents to wotect th*T th'ldren by askJr#J thur <h)lors at(Jut the knmLmlsats)n.
HPV Actton Romarkn was Lfficlalty laUrKI￿d, arrfl an in<ounty Cofxthnatsr aFvointsJ, on 31 OIXcèw at the
HPV Actw Now e￿t in the RorNinian ParfiarY*rt in ButhèresL At the estn¢ Romank s health mlnister,
Akxanthu RafTts. announced bxit erwj of 2023, HFV In￿Vro$at1* woukl ke fulty ￿4mbUT$ab￿ by the
*ate fc¢ all boys glrL4 11 to 18 years okl. AJihwJh tfre￿ ¥e stlll bèrrfets >Ah as dellvery and distrlbutlon,
s well as combatiro wblbc mbuNl*stJndiNJ arnl misinforniati￿. th15 cixnmlthEnt Is a 9gnificanl Step
Croaya Intr¢<1uced GNV in 2016. immur¥salxm OYtrdge15 ¥￿1 bdow VIHO ellmknaiSon trrgets 0190%. In 2023..
Crothn pc4*makers were In￿t￿j to an thrty ottc4>er the coalkn cl natthal SUPFKJrters of
HPV prevention, hlghllghung the rnea￿ nat5onal aThJ Ictal ￿ganISa￿￿$ Can 9JPPOrt advocacy efforts
to enC￿jrage uplake of vacclnatrffj In crfder to prevent HFV carws. 20 Octrt)tr, the group pawtiapate(I
In the'stskeholder Forum "8etter H•alth for All: EU Glo￿1 He•lth Str4tegy', overviewing the
upcoming pkns for the Coallkn and wesertlThJ the akns of the w￿C￿lI¥j can￿r SCTwlng Fwrams
In Croova.
Throughoui 2023. the coalft￿n was In ￿ter￿￿ on Noming Cmatia,, whith h)ve
emphass8J the preventsbllty of HFV cancws throlth ImnwJnsaUon, aNI have highlpjhtej the underu￿11$￿tIon
of HPV vacdne5 arr*￿j wJurwJ pec*, to a n)tb)r01 audvKe.

THE HPV AND ANAL
NCER FOU
DA
HPV Artlon Croatya wa5 ¢)ffidaly launchgj on 6 Cecerniv at ￿ Croatkin padlament hosted ty Lvan Cdid MP. and
rtualty vk YouTute. Brlnghg togthr exFvts frcffi epldemK4c*Jl#s, ￿lL7￿# PatJgrt5, gxiety groups the
aim is to ueate a united appycoch to wnF*ove Pre￿ in HPV.
Buloarla
In Bul9ari), the HPV Attion pro￿tt anns at bn.rory togett*r, unltlng and supp)rtTng cryanlsatths and
Instltijtions that w￿k tthyards HPV ¥acanatlon and C￿¥￿al cancer sueening.
Th65 campaign ￿11 be coc¥dinated wth Bulgarkin HW c0altty￿, a naomal expwt nM4Jovemmentsl coalltlon
acrively supwrted by the World Heath Ownkauon. Ifs obJthe5 we..
Raising put4ic awareness aroJThJ the risk IA (￿bThJ tt* vlrus,.
Encouraging regular Sc￿nirlj,.
Athieviry a hlgh I￿1 ol vacdnathjn. In &X(Kda￿e WHO recorn￿￿jatb￿S.
In 2023:
On 19 Septernber. 1epre5enktl￿ HPV Aclth Nthoth ￿bj?rian HFV coal￿10r¢ had a fruMul
meets'rvJ in Sofia at the Bulgarfan ParfL4ment k(al MPS encoura￿d to c0ft￿nue efforts toward5
HPV prevention thr￿gh vaccination.
Held M 10.12th No¥￿b￿, HPrf Actth metr￿rk reWe$￿tIVeS spoke at tr* seccmd Buhjarkryn natlonal
conference on vatt1ntrp￿￿Itrb1e diseasts, kir9e# thent e¥er In cc*Jnty dedkated to these
toplts. orYn￿￿1 BuWrK4n HFV coalit￿ and Astra Fcyum FWThJ9t￿, speclalbt In vKclnatk)n
TrJ preventyon con%tnel lo wojress aTrJ challryes wlthln BU￿art￿.
Protert Europe
The EU4Heatth pr(gr￿n￿ was adomed as a ye5p￿se to the COVID.19 PBTrJemK aThJ to reIr*0￿ olsls kyepar&Jr￿SS
In the EU. The paTraeM￿ highlig￿ the fragillty of nat*)r¥31 heath syst￿nS. The EU4Health progromme wlll bdr
contnbutlon to the w.term health chalberw ty budding 5trorw, rrKYe arKI mtye aCc￿￿ble health
$y5￿S, thrcmjgh firwiclal support from the European Lhkn.
Through thls lundlrrfji the PROTEcf-EiRC*E woject wll dNimpk)n gvthr-r*utrnl HPV vacclnatim In tr* EU to prote£t
everyone aga1[￿ HPV wovkling infomwixjn arKI gu￿SarKe to EU meMtr￿ Strtes ￿.
How profesYona15 better communkate dlredly 7hith young peth and thelr parents or
raregfvers,
How rre55agwNJ on can be tsIDw&Y to tkn retywte with yyjung pojple ￿ thelr parerts
or caregivets.
How other approa￿ ￿ as l￿ThI11r￿J var¥￿5 athknnt ￿lnes, coukl knprove HPV vacdne
uptake.
A key e￿n￿t c¢ the prOj￿t b ensJrfThJ that Lw5 os ￿11 glw15 are offered the vacdre. Gendw-neutr)l HPV vaconafjon
Is one of the fi￿sh[P comnknents c¢ Europe's Beaung Car￿￿ Plan. Andir¥Js frcrfn thls project will contribute to the
HPV AC￿C￿ ￿Ork as tr becnme avalatle.

E HPVAND AN
Re5POnse to Europ8•n c￿nmI%1[0n call for •¥ld•nu on •ctk)n to v•¢rlnatkn •galnst cancw
cau51n9 vlruses.
The HPV Act*Jn supp)rted a re5￿p￿e to the ELW(wn ConwntsS￿ Call Ev*le￿e on canctr prevention -
tion to promote vaUl￿n aga&￿t carw-caulffj vlwse5. The cfjnwttafjon irwited pU￿1C feedback on fijture
inibabves to increase uptske of against ￿ Hepatitis B VINS Human WlkMnaviru&
The ull fty evldentt ￿11 sUFVOrt the (kafarrfj of the European Ccrfnmission propcsal for J Council Recommendatk)n
on vaccine?re￿tstAe cancers, vthich will te publis1￿d by of 2023. The HPV Action Ntho￿ empha*sed the
ftAlowlng pdrts for IndusK>n In the Rec￿mendatI￿.
l. tr* achlmnent of HPV dknlnatm thrn￿h wder-nelrtrnl va¢£lnaUon.
2. 1r￿reaShg cobtrage of HBV vxdnavrm lTr**llr4J kn new-t#xns. thklren tsk4Jr￿ps.
3. Ensuri￿ an inequalrt*s fcojs thrO￿9￿ut the recom￿￿.
4. ActNety trathrg monttodrvj kYC#3ress tth¥ards of HPV and HBV catKers elimination go81s.
5. Enhandng EU level &tts)n agalnst rnI￿nf(Thatic￿ arml d￿nf(￿Matkn vxdnath)n sockil rMe4a.
6. 9)pp￿ry J stable s(yply •)v6ronment for HFV aTh1 HBV vaccw*s acr(6s Eun)pe.
7. CreatÉng sYnerg￿S ttheen the EurcFean Commtssb)n the Wcrld Health Or9anization In [M￿ementI1
jlicies sirategies the diminaticfi of JI dise•ses caused ￿ HPV and HBV.
8. Urglng Men*er Statss to adcrf public healthStrdte9￿Sthat kndude mukn'astskeholdtys eduoth)nal campalgns.
9. CUnm￿ln9 Member Siatesto ￿J￿fa￿1trte access to VacCha￿On aThJ ty ImrAement coydlnated vac£Snat#)n
catch-up programmes Jmong tl* ￿P￿ation.
10. SecurirYJ kjng-terni ccrfnmitment Eur¢ye•n Unim to the fUr￿lI¥j of ¥&dne•reVentab￿ ￿￿er5
research.
Future plafts
In 2024 and bey￿d, thè HPV kb'on Network wil:
ComF4ete the PRoTE￿.EL￿OPE proJeLt and utllse Ihe (XW posgt4e for Atlbn Now.
Continue to SUPF*Yt the national campahjns In B￿garIa, fJoatk arKI Romanla aThd acti￿lY cowder eyparn11ng
the approach into Poland arn1 other cwntries whwe [￿L*.
Plold an AdvcKacy Symposlwn on 25 JarKory p￿1th a folhyhwp rrf￿rt. We wll learn the knons frorn
the SYmp)￿uM for wcfk and erKowage othu5to utltsetheoutwts ￿ th*r own campalgrks
on HIV p)lty.
RespoThJ to the fc*thccffjlTrJ EC proposal ts an EU Coundl Re￿c￿Mendation on vacarE"preventatk cancers.
Continue to dissemlnate and use 05 an a(fv(Kary the EPFIECO HPV Prevention PolKy Atlas.
Use ECOS firne to Acceknte Manifesto and the Men and ca￿er RoMJmap to ralse HFV iSSLf5 during the
European Partiarnent elettions.
Continve to Paitipate In the M15sion P4)3rd on vacclnatlon chatrd by Pft)f Walter Rbdardl.
Partlclpate in Intematic¥h4 HPV Awarerw Day and Eurwn Immunisatim Week.

HPV CO￿ltIOn UK
In October 2022. the NOP+iAN Carry)BtsJn were proud to k4n for￿ Tfftlrth kJS Cthfjcal Cancw Trust to I3￿ch aTrJ co.
thair the HPV CoaMIkn in Uniteil kn"ngthxn. Tr Coalrtton was officialy launthd in the Pa*e ol Westmlnster In
an event hosted by stsndiro HPV &Jvttats, Jess ￿111￿$ MP. arxl supwted by rditlaans frorn both 9des of the
a￿e. •$ as communty #aktholdtrs such as HFV carw ￿.
The HPV Co&It1￿ i¢ •n exW grw of kodlng palknt grws, grwps, dIn￿an$, and exFert
kndlv4duals who have come togettw to Inforni and U￿$ bJm* towards elimlnatkn of HPV-reL4ted
canttts- cancers atccwjnt foT 5% of all 12nc*5 gk4)3ly. and wA)l¢h rthi. for the flrst time In h15tory. haNe
the opFortunty to dlmtnate a5 a wbjlc health threat
Despth the xale ofthe orwtuftty, the UK has trtt trj tske the step cldher countrks, suth as Australia aNI Canada,
In develcplrKJ an plan for cervkal carKer eliminatkn. The UK a150 ljgs bthlTrJ ￿ Ewopean Unbn %%thlch,
through the Beatiro Can￿r Plan, has sw? fvrt￿r, In commltting to dknlnate all HPV CaT￿r9. The H
C031it1on Is the￿fore eager to see the UK F¥Jt in pL4¢e a ¢￿￿rete pkn ftr el*ninthn as a matter of wlorty, target&1
at the while rawe of HFV-related On￿￿$ ￿p￿tir￿j access to pTeventstJve interverticfis for all parts of the
The Coalllhjn wlll sI￿d at the luefront LK rK4*makJrwJ and vlll Mng together J memt•thlp of pat￿rt
oryanlsaljons, pro1￿Onal groups. dirwcians. and eywt indNhJuals to aTrJ denKJnstrate broad staktholder
c(Jr6ensus artsjnd the Sign￿(anI - and as yet unharnessed - C9F￿rtunity to pur9Je elimination in the UK. The
membershlp wlll for commthent and actth from Il IX govemments to wrsue elirninabon of the whcle
range crf HpV.￿ated cancers, in LKth aThl women.
Publkatlon of th•'Ro•dm•p tow•rd• m•klng the eMmln•tlon of •ll HPV-r•l•t•d • r••llty acro
the UK.
In May 2023. t￿ Coalttjon publlsw a Roa(knap iowarfts makkng tr* ellmlna￿on of all HPVYelated cal￿er5 a reality
t<rcw the UK. Thls sets out amtrxbous, yet reall￿]¢ wts, mawrKJ OLrt kty areas of Jthon. IrKludlng milestones,
The Roadrnèp seThts ès a to Govemments across the r￿Jr naticrs of the UK to tske athon, Whi￿ provldlng the
blueprint of hjw ellmlnatton can be de1￿￿Ted. Tr goal Is slm*'. Make the dlmlrofjon of all HPV.relJted Can￿r$
reallty across the LIK. We have many of the tooLs avalable to us now to n7ake a realty, and we must ensure it15
grasped wlthout dday.
To achleve th15, we must ensure fMdatkNs of HPV prevenkn are strtyhened. The Ro)dmap Ls th￿trOre made
up of a numbw of buAdlrvJ blc¥*s- vlth a$s(￿ated acth)ns- that to elminatim..
l. Nltional and regRY￿1 le&der&lip ar#1 acC￿ntabl1ty
2. Improvin9 alucatknn on HW to tackle stlgma drive acLW to prewentk
3. Maklng sure everyo￿ has equftable acress to sueening aThJ earty dIa9￿615
4. Restorfng and bcost1￿ Immunisatk)n Uk*ake. Ind￿kng (atth.up proJrammes
5. Enhandro the dats, digital aThJ workfrKtt infr&4n
6. Embradtyj fu￿re innovatN￿s
io

It ts CTltkèl that UK gov*nrw)ts set a oyKrete strnte9y ftr tre arnlnatkn (rf al HPrf.rel)t&1 Ca￿0J5, hldenkng
the scope ofour amt4tion orKer elhninatkn. ow felkxv memb&s ofthe HPV CoaFJdon. we
and te* to gJPFQrt the of TKomrwxlaIk￿ aTra tr** meDrwJfiA * to &YV4ert PW/.reL*ed
Urm *s p￿ICatIC￿ tr* Ro•thnap nolkxba ur4voge at I￿rKh, an.OpEd autfrfftd ty the
Foundatkn's CEO Davld Wlntefft¢d kn The Ttrne& it hos akn ￿atIed ￿ G)ally¢￿ to engage psky ar¥Y
rf*amentary stak&dders to faclht&e whjer arothi1 ts rnadffl￿ ar*1 ulbmate goal Lrf ellmlrotkn.
Th1$ Includul a Weknwn#er Hall HPV vKtsnatlon •ttathJ by MPS a￿1 n*ir4s wth UK Health
Seojrlty Agery (UKHS4) the gKwtrnmert rÈswth for E￿￿￿.WIde pubk hèath pr(rttttlon Inlecdous
dl*ase capèblllty, NHS Englar#J, an to IO Street kn brfdtre Mlnffith He*1
In November 2023, NHS thld execl￿￿E F¥ft¢hard p*d to eKffthate Ca￿ ty 2040. J key step kn
the fr)urrw tr) the dnWnaUon of al HFV oncers. In De¢en*•, NHS EThJWs first Vacdnalkn Strrte9Y Was
publlshed c￿(nIr￿J J f(xu C￿ knytr¥lrwJ HPV vxdnth cow rntss.
In 2024, ￿ Coallth)n erwge NHS Ewd x a partner In the ￿p￿m￿t￿lICI) of the ewftknkn ambilkn,
to e￿re that HFV at the tcy of ts wKl• be a dwrge (* wemment. We WAII work
wth local syst￿￿ to knyove HPV and to fty commItrn￿ dlmin4W¢m In the
de#thed nath)r6.
Lthdlw th• dmrge for global gmdtr-n•uhl MPV ¥•(*ln•tlon
In 2023, a record nunknr (rfctyjths aLW iws th* vxdn•UM pr(*¥•￿, 4lor45th glrfs. But gendtr.
nejtral HPV Imrnuthtk￿ wwammes, to cancets. Jre ￿11 Cffb
ullsed In ￿ rrfmrjty of prowanms 9￿ba￿. Ifthis year Ls to 90 by, It be rase for kng.
In the pa# star we hast seen IrKs635ed Va¢d￿ 94Wles avaUalAe. nE+V sbJ¢k$ 1I9hllghtJng the effeLtthwÈss
ol wKler.neutrnl ImM￿lsatIon, kntJeasoJ Cal￿ for I￿(￿1)n ry* vacrkne gwKler•ality 9rourbts, tr
OPPthinSty to spwj up progress of cerviLal ancer, aThl In tum 411 HPV Car￿ Yet tth
SUII 5srrk to be dfft. N(N4N c(x)Unues tv lead global effryts for Ihe iTrJusb)n of boys brto (￿ntrIes, HPV
ImmunLs&tion prografflmes. In 2023. wefr**d the Global Hprf Consortjwn's laur￿th In Kual) Lumwr to s(we the
fra￿e￿OI* to t* glob41 on onc￿, sp(*e at a p)r*l drsasskn kn W2ium.' Ellminail)n of HPV QrThs:
Cyeam or Rthfty7 {RE￿rrY11, In aldjtkn to Gc4)al on m￿.5 ￿1th IGWH), as dLKu5*d
tekny.
In 2023 W￿ annwrKed o new ￿rtne1th￿l KX4IWI 1slvKI.. Rxe to ErKf HPVGThnpaiw aTrJ 13obal ILlfon
on Men's Health (Glmll, ￿ c#yanlsatk¥) dedL*&l io health and hou-belrg on a knl ￿ale. Tc*ethex
we are embarfvthn9 a m15sh)n to ffwJre knl Unl￿01 actss to Htty vac(inath)n, a vtsl
li

FOR THE YEAR ENDED 31 DECEMBER
Why 15 thi5 pathty5hip (nKial? HpV￿￿ted disease5 affert nMllon5 wryklide. wresFth of ￿. HFV can cause
• range of t4￿r5 . cer¥iol, anJl. pende. win4. vufvar, lwd and nxk - as weu as g￿1￿31 warts and recurrent
rewratory pa￿llOmato5￿ (RRPI. Yet gender-neutsal HPV ￿￿(Inat￿)n. dryite now Leing a Ylagthlp, carttr prevention
Follty In the EUro￿n Unlon las detslled In Eurwets Beatkng Han, 20211, ts stdl cfflly the gdd stsndard of
otects.on in a minority c( HPV vKanation projrnmrnes. In most Count￿ wfth an Htry vactifi￿n wogramme, only
girfs vaconated. Gender.neUt￿ vaconatr.on remairts a controv￿1 e5teoalty for lower4ncome countrles
w￿h very hlgh ratesofceNkal rarttr, arKI ts not yrtfvlty r￿fy￿r￿ded bytr* Healih OfwuSat￿n or 9JPWrted
by GAVI.
By loa&r4 onty on the of girfs to (en￿*1 rarKer. glrts￿ty prc4Jrnrnme5 fail to wotert males
sufficientty from the cancers cw5ed by HPV. They also fail to proted urwacanated women from inf*Xlon by men. a
particular problem ffi countries with vK(ination rnte5 in girfs. Girts<ffllv Fffogrammes akn mean thry unfalrty
shoukler the resForsltAIty for preven0c￿. Wlth vKdne Supp￿ InC￿￿n91 slngle.dose wgramme5 charyln9 COSt-
effeCdNtr￿ ￿￿kitiOr6 and e￿dence 5howlrg that 21% of male5 have a h￿Jh-rfsk (can￿rOUS1rIJI HPV
Infedkffl (Buni L et al. 2023), it15 tkne to make the (Bse for ￿1￿1er.neutraI vxdnouon on a global basls.
By ad¥C￿brrfj gender-neubal HPV v￿rina￿￿, we we safeguardiThJ the hearth of current generavorts, male
and femak, Lxrt also pathg tr* way fr¥ a futwe *tsre FWV.rel)ted oncus and rfiseasts are ￿lic5 of the past.
Worldng In collaLhybtlM, and P40MAJ4'5 partnwshlp kn 202312024 Vdll entsl,,
Lkthirvj an ose lor gerWr*utral HPV vaconakn gb*aly.
Identifylng the key stakehc4dus for partnwshlp and P•av¢xacy In each WHO regkn ¥Ath a frKUS on thtsse
reghThs wlth countries rffthng gender•f*Utral vatdnaii)n
BulldlTrJ an Internattonal alllarKe for attth on g￿er-n￿rtral HPV vacchwuon.
Anal C•nc4r Found•tlon
Anal Cancer L% one ofthe fJste5t gr0￿rg carKers in the Unfited Ststes, stsadlty InoTeashg In Llnited Kin¥lom.
We conty'nue to work tirdesly to rnoke I'fe better for fJrnilie5 anjl 13rw through wr wograms to raise
awaoness, xcelerate eatty detect￿. improve qua16ty ￿ rife. arbj alfvano a awe. This year, we made In¢Thdib
progress rnlsing a￿rer*s5 ab)ut the need to ref￿ h(w caKer thriv•% ao dlagnosed and treated.
P••r to Peer Support Programme and Thrlver Educatlon
In the UK, about 1,500 pwAe, arrfl in the US. 10,5CiI are diagrK>*d ￿th anal cmr anNIal￿. Anal can￿r
Inciden￿ Is IncreaslrKJ aTrJ afferts rrKrfe p8)F4e across ewy year. The 9xlal s￿9Ma that anal rarKer carrfes
preverts fair aTrJ eqLltsbbe corNusali)n, awareness, and t￿￿n9 to sLFpl￿ researth *)d carè for people wrth the
dlsea5e.
12

EHPV
E TRusfE
Supptrt and Infor￿￿tkn Ls limlted anal caw thri4w ltyjr fDT wrvivors) many thrivers Mer meet
another anal cancer F4tient. The yovldos forvms ar*J a peer m￿tOr1￿j program to support
thrlvers to dose this gap. The Peer to Peer SLVWt PrryJram 6 a free seryKe F*owded by the F￿Jndati0n in the UK
nd USA to connect pthnts caregl¥ers fa¢irrfJ the thal*s Lyowjht on by anal wlth a peer who has
ur*ertaken the S￿￿e joumey.
Conrths a￿ avallable for an￿ne at any stwje fnMI rthyty di491￿ed to years after trethent. Vdunteer5
Ilsten and help thrfvers Uwough thelr (arKef j￿ ty sha￿n9 their own on treatmenL stSgma a￿1 soclal
experiences relatin9 to an onal cancer dvagnosos. The pr(wn￿'S 9oals we to irnp￿ the lives of those affeLted by
anal cancer and glve a Yo￿e and a ctffimu1￿. Tr* program aLw rnatd￿ orE9lvers tcgether. At the
of 2023, the HPVACVS Peer lo Peer Swrt Prcornm o￿lUd￿l 1199 thrlvus, carek¥vets. and pew mentors.
Our onllne eduCa￿c￿al events contlnue to provkle and rexJurce5 fw thrivvs. Ta￿ng Care of YLXJ.. PJlanaglng
Slde Effects from Treatrnent For Anal Cancerf featuring exw dinKlans whotreat peoF4e liwng anal cancer
as wel as a panel of t￿1verS ha5 teen by over S.9￿ the end of 2023. 'Liwng and Thrillng ther
Treatment for can￿r. Wressong Lw Tem Skle Effertg. was 11,OCKI til￿ ty the ernl of the year.
An•1 Can￿r P•llent
on ￿tCknr 21sr 2023. the Anal Canctr F￿r￿1￿￿ the s￿)rn1 Anal Cancer Pat*tt SunmlL
Medlcal professknnaLs 5Foke ab￿rt car*tt cwses, tre41m￿, and h(M to mldgate the varhws $￿e effects of
thLYnoradlation. We also heard from othrotes th taLght us, through sharfng thelr own rtortes, to use our
personal exper￿n￿ to advaKe the fight a9aknst ènal carTh. Flndty. thrsvers We￿ abk to netwc*k b¢th in groups
and wlthln one-￿￿￿ sts510r￿ whlch. fDr w pe￿, was tt* tyme ￿Y weo meedrvJ a thrlver.
The conference was ueated to kvovide an annual cppryiuth for anal carw pat*nts aTrJ care9lvers to learn Irorn
medic41 profe55WiaLs. conr*rt with experts and eath othtt, aNI lake ac￿￿ to empo*¥er th&n5elves thts
communty.
Over 449 peoF4e reg&efEd lor the from 22 ctyJntr*s *tyJnd tt* W(￿d.
Anal Cancer F￿v￿lat￿ CtrFounder Jus￿r￿ Ajmada f&irth￿ the dtys events. EX￿rtS induding Kevln Du, Caihy
Eng, and Pavl ROn￿ser SF4)ke at¥)ut anal ¢auw. treatmerts. emerglng ￿r￿es, aTrJ qualty of Ilfe after
treatment. Thrlvers bvere glven the CYp￿tunIty to ask qwtions Ilve. as hEII as to connect with one aTr)ther.
We 45wld Ilke tts make gjre every faciw ha5 rn to the sarr* irfLYrnatlon as thelr d(Ktors.
RecJ)rding5 of the davs events are avalat4e on YouTube •￿1 hos 1S(M) ￿e+¥s ￿nce thwr publicath)n.
13

THE HPVAND AN
TRU
Int¢rn•tkn•l Anal Ne0pth￿ Socl•ty (IANS)
IANS, the Internticrnl Anal WL75va Sc￿￿ty, creates gul(1dl￿ aThY ￿[s￿rts reSea￿h essential to
i)reveniirKJ arKI treatirs orTh. JANS was ovted wAth a seed grant from the FouTrJatM.
IAMS m1ssc￿Is to a forum fc* wAth a broad of backwurvj, vlthvonts and gec¥Jraphlc
ot1gln, an exchange of Ideas atvj th￿￿nat￿)n of re9ardiThJ the pathcgewls. diagnos15, treatment •nd
preventkn rf anal neoF4*.
In gJPF**t dthls ms4on IANS:
Cevew positKm P3pus regbr(&ng the trtsitment preventkffi (A anal rwIaS￿.
ReFfesents the oF4nlon cl IANS regar(ling the tOPiC5 to other professlonal publlc
organlzatlons, reguktory aut￿)N￿ aThJ 9ovemmentsi Ly)die5.
Encourages the devdopment ol a robust research agthda on the pathogv*sls, d￿9n￿5, treatrnent and
evention of anal wfAasla.
Develops educatl(Ywl materlals and tralnlThJ courses Ihat e￿rage the enty of a broad SFéctrum of
clinloans into the r￿d of anal neopla*, arml that furttvs and depth of skllls of clinicians
needed to optlmalfy dIagr￿. treat and we¥￿t anal n*a.
r*vdco eduothjnal materials for patierts tmth a￿1 r*cylJsw.
Inforni•tlon and C4￿￿•cO0￿
The Foundatlon's Jnol ycgrdm vrtbyte leaturts a of resowcts ￿ Is J ￿Tte of inforrnatlon. supF<*rt
and In¥ratkn fc* iknts and lamilies affected ty anal ar￿.
r focus Is erfjurlng pailents get the Infwmation aThJ Supp￿ they n*d durTrrKJ their anal carKer Journey. Our LI￿n9
AnaIcar￿rsecoon featsjres Infwnatkn for patlentsatall sbjes oftl)e anal caKvJoLwfrom newtydlagtwd
to post.treatment resources. s￿h as ￿)W physcal therapy C￿ help with anal carTh treatsnent recovery. The site '
the mo# ccynwehenlve source of informatlon Yde effeLts the effttt mlljgation durtng and after anal cancer
treatment, This digital fvJb $ kwlèted with pergjnal thriver slories (Fet*nIs.sto￿ oftheir experiences), infomwtion
at>wt helpful medtal rttources, aTrJ kyofesgonal medkal L¥)d*s. as wdl as Connecd￿ to other patlents and
¢are9ivws throusth our Peer to Peer ￿pport Pr(rfJram.
r goal In 2023 con1kn￿ to be e￿rIng that mtye tmvers hm actess to the Inftymat1￿ they rwd
to face they carTh ioumey through tal￿ts1 ￿￿reath based u) wr suppxier base )nd o ne￿￿etter ser￿S
for patlents and Care9￿S, fOC￿e￿ cffi ¢wr exret aThJ Fowlar reswrces. ccffjrThJnications trdtegy contlnues to
focu5 on conslwcy and provkliro-uselul" infmtion. contentCo￿n9 treatmert and r￿rch UF*Jate5, strles
from cc¥nmunlty members, a￿1 explairws of￿1 servlces and hcw we suppxt the anbl communty.
14

THE HPV AND ANAL
ER
NDATI
THE YEAR ENDED
IDE
EMBER 2
ACF'5 2023 di￿ impxt indLKks:
185 new and carKer thrivus and rJregNUS 9griThJ LV to be matow thr¢y4h the Peer-to.Peer Supwt
gram.
330 anal ￿n￿r caregws Wped by tr* I:1 Patr￿t Navwtion knice. Peer to Peer &Jp
signups in 2023 are up 49% on 2020 frju￿$.
7 thriwers sharing their story publicty with our community Share Your Story Inltlau
650+ Pecy￿ partldpattng In wr infomkibonal frxurrs.
lknrall, In 2023. ACF dlrectty ser¥*d over 1,10) anal Ca￿er pa* our best.i)<lass patient prc#Jrams, at
no cost to them.
Jiw forward, we wlfl to provKle al the s¥yxt the anal oncer c(ffimunlty need
Looklng Ahwd: 2024
As we kKJk ahead, the HPV Anal CarKer Foundouon conthw to seek the most effert￿￿ mett￿lS to prevent HPV
an￿ cure the Can￿￿S It causes.
The Fclmdatlon wlll COn￿MIe to syork tlrdes* to eliminate all Hpv￿e￿1t￿￿ carKers by fvrt￿n9 pubwc pollcy and
sclentfflc debate, elic*lryJ fvrthex Vofe￿I eypert suprt erKowaglng the development of reg10Th31 Inltlatffts
on vacdnatlroj boys, and derncffjstratlTrJ why Is irnF￿ant to wotect all th1Sdren a9alnst HPV at the recommended
age.
The UK ttyan vaccSnatirwJ W against HPV In SeO•)*er 2019 and will c1￿¥nue to work wlth stskeMders In the
HPV.retsted dlsease Space to e￿￿re that uoake for thls Can￿r￿￿n￿¢y4 inteTrention amr4J I2-13-Year￿￿j boys
Is as hjgh as possib￿. reb)uThJlng from ￿ dlswptkni tr* Immunlsatkn prcrfjrammes caus8J ty the paTrdemlc, ty uslrYJ
the cdlectI￿ knowledge of the HPV Coaitti)'s n*rnbershlp to w$U￿ that the Opwfvnity to ellmlnate HPV oncers
1rnt￿UK
r &lvocacy efforts in Eumpe with the Euro￿ Caw th9a)Isat￿ Hf•l kfjon to attain geThJer
ne(Kral HPV vacdnalon atross the ¢))niinert, ak>3ce. Wlih the EU BeatlrKJ CarKv Flan Specifical￿ IrLludlng
rtiors on HPV o￿tr$ within ts remi( we have a mandateto 9oin 5UPF#Yt and ernp)wer staketK4ders within member
states t¢ eliminate HPV With 410% of carKers in region preVentsb￿, the exten4on of HPV vxcinakn.on
prcgrdmme5 to pro￿ Lw5 a5 Y￿1 as gir15 pfovKJes a recwifed and effertive rnear￿ to tsC￿e canty. By contSnuing
to build our ewdeno base, seekiffj and identiNrvJ barr￿ to uptake In EC member countrles, harrEssSng the
possibllttles pre￿d by Eurcpe's BeatiThJ Flan and laumlirKJ akncacy groups in memter thtes, we are
confldent that r￿re countries W￿11 agn up to neutral pri￿￿0￿ In1tJa￿￿. A(￿rtIo￿lIV, y￿ will ￿lId on these
natk)Dal aTrJ regional er￿eaVoUrs, by tskiro our campaign gbbal in 2024, workj.ng aobal Actiorn on Men's Health
will develop an evidenctrbased case for gh)bal ￿d￿-nwtTal HPV vacanatsn, and Jts'li5ing hpjh.kvel symposlurn6
s￿h as Worfd Hearth Assembty and theW￿ld can￿ c￿Te$S to rec(#Jnkn. ark1 an knternauonal allkince
for gender.neutral HPV vacdnatth.
15

HP
li
Thrw the Pa)14AA 5$ an I￿a￿l Campalgn, collatr*irationsth afvocates aTh1 legislator5, rnedla attention ar￿ athletic
event pa￿(￿PatIon, a broader L% Unders￿r￿rWj the of prO￿1v4 all thlldren agwnst HPV. Wlth
the NOMAN sde oftr* ￿ganIS￿)n *aJirwJ ￿ Hpvthrek￿ actpiit*s. ow platsm is grcwing frcfft which to tYoatha5t
Lwr message.
We wll contlnue to wsh legi4atfve, research a￿1 F4)Iy ¢JwryJes to end anbl carw and Imkyove the lfves of those
affected by IL We are e¥ated ty the rewse to wr Pat*)t Sunyrmt ￿d"Ask the sessions and 6ook foNard
to provhling more touthwrts for ￿Jr ccffimunoty In 2024. Ow Peer-ttrPeer support tyogram retsln5 Its ImFQrtan
In sUPPOrtirv4 and anal can￿r survwrys and ¢aregfva% Uiilizlrvj digrtal pL4tforms, we will reach
a wlder proportbn c* the anal car£tr comrnunwy, ￿￿11￿j pattents to galn *wNers tD the corKwns have Jnd to
cenn￿t to other anol c3rKer pat*rt e%￿er￿s.
We th￿k all of ojr doThys and hx>k lo￿ard to crtknimng missKffl to unpowtranal cancer patients accelerate
PreVen￿On and researth rDetWs that ellmlnats anal car￿1 and the vlrus that Ca￿e$ the mafvrity of cases. HPV.
16

The tn￿eeS (WIKJ are akn the dffttols crf Tt* HPI •*J Aro1 Car(tr Founthkn Lknked) for tr* wrposes clojmpany
lawl ore resrons*4e wepathg the Re￿t0ftheTru￿lTrl the fina￿]￿ statemwts in acrordarKe wlth appltable
law and Un￿1 AcC(Art￿j star￿ords ILWted (kna1￿ Acceptsj Pawntlng Pradice), i￿lUdI￿J
nandal Rep￿9 Stsndard 102 Tr FWn0￿ RwbThJ str￿ op￿katIe In lfv UK ar¥J Rq)utrAic of Ir*￿1,
CoMp￿Y law the tr￿tee5 trj wepwe fv•rthl ststements fty e*1 flnandal y￿r tNN¢h gl¥t a true and falr
of the stste of affairs of the charltable ar*Y of ￿ irKtynlr#J resouTce5 a￿1 apr4scatK￿ of
Ind￿lIng the knKcrfne and ex￿n(￿t￿re, ￿ the thgrrtth c(Mmp8ny tr th)t PtrKKI. In txgp8rlNJ th(se flnand
staterneits, the tsu5tee5 are rewlred to
sefert sultst4e •c¢0￿￿n9 aThl appty them (￿￿erth
Ihe meihc#ts and princi￿ in the SORP
make I￿JgeM￿￿ and estlmates that a￿ re¥thit4e pr￿
epare ￿ flnanda ststtrnerts gokng corKem ba￿$ unkss * Is InaFwrfa* to
E5ume that the dwrttatle cornpary wll contknue In txtslness.
the finarKI)I pc6itOon of the tharftable Cr￿panY and to en*le them to ertsure that finandal staterrents comply wlth
the cCfflpB￿ 2006. TW are akn resW￿t￿e for gfegwrdlThJ the assets of the chathble compbny 4r*J I
In 9> tsr 45 the truts are aware..
therels rw) relevant knlormatkn clYAlch the dwrftst4e £ty￿an¥s eDmWs are unaware; arKI
trustees have taken all steF6 t￿3t thry ought to tsken to rThike themsel￿ awa￿ of
The IndeFthlent t¥amlMr, CJoryw LLP, be prpoxl for rt4F*nlmert ot f(xltrth))mhYJ Annuol GenuJl
MeeVr¥J,
rwt has betn Nepara1 kn actrydJKe *lth the ¥￿la1 Part 15 (rf Act 2Crf)6 rejatlrvj
to
APPROVAL
Thls reFQrt was by Board d tXrectors ar￿ Tru#ees on ￿ Sknnl*r 2024 *ned thdr behair
17

I ￿port to the dwty tr￿ on my t¥￿￿￿nati￿ d the Kcwnts d the c￿anY ￿ the yw end&J 31 December
2023.
Rejponsibilltieg •nd btisis ol report
% the trustees Of￿ charits14e compony (and akn ts d¥ettor5 the purF￿SeS cl ccrfnpany law) you we respo1￿￿￿e
the preparation of the ac£ounts in ac(Crfdan￿ ￿￿th the requirements of the Companles Act 2006 {*he 2006 kt?.
Y￿j are 5aYsffed that accwnts of the Company are Tr)t requlrwj by (harlty or o)mpany law to be audrted and
Havlw satlsned mysdf that fv amnts cl the c￿nY are ￿t requir& to be a￿J￿e￿ under Part 16 of the 2006
Pct and •re in(kputhnt eYan4natK￿, I rewt In rewt rA my examlnab"¢t) of Companys accounts
carTied out under se(O'on 145 of the (￿antIeS Art 2011 Cthe 2011 ALf. In Ca￿￿g out myevjminabon I hJ* folkn¥ed
the Dlrectkjns glven by the ￿aTrty CthnrNssMJn ￿jer seLknn 14515Xbl of the 2011 I<t.
Independent éxamlnerfs statement
SIn￿ the Company's gross Income exceeds £250.(￿ eyariner rn￿5t be a member of a Ilsted kn sethon
145 of the 2011 AtL I ￿firrn that l am qU￿lf*d to u￿ertake ￿ ebzmiMt5on becutse l am a re9lstered member
of ICAEW which is of the listed Lvjles.
I hove corn￿eted my exanMrwtKJn. I confinn that rK* fflatter5 come to my atteniith In ccfir*rton ￿th the
examlnafjcffj g*lrrtJ rne to bekne that in any matsrfal res￿￿.
l. accountlrKJ records not kept as requlred ty seLtiM 386 of ￿ 2006 ALt;
2. the accounts do Trjt accord wth those rectyts,. or
3. the accounts drj Tr)t crynF4y 7Atth the accountlng wUtren￿ts d sttuon 396 of the 2CX)6 Art cther than any
reoulien*nt that the accounts a Irue and law w+tith is not a rkwtter ¢))n￿dered Js pjrt of )n
Independent ejaminèlion; LY
4. the accou)ts have not txen weweil ￿ rKcorthnce *ith the methLth aThJ prirripks of the kntement
Recommended prdth￿ for a￿Ount1￿j aThJ rewtlng ty charities a[￿kab￿ to d)arltle5 preparlng th*r
Jccrwjnts In accordan￿ the Finanoal Rrfkni'w Stsndard aOicable in the UK and Republk of Irekind
(FPS 102).
I have no concems and have come •yoss no ckner rnatte￿ In connethon vhth the eyanwna￿0n to wNch artth￿c
shwkl be diawn In thls reptrt kn tyder ro Wbabk a woper uwwkrskThllrrfJ of the ￿£￿nts to be read￿d.
Rithard B￿lIr￿jhur$t
Knox Cropper LLP
Chartere(l Accountants
65.68 Leadenhal Stree( L￿n, EC3A 2AD
2610912024
18

THE
COME
2023
Total
Funds
2022
Total
Funds
Funds
Funds
INCOME AND ENDOWMEIITS FROM
DOna￿on5 and Legades
122.220
122.220
90,094
0￿r TradiryJ ActiM￿e$
Invtstmert Income
457,311
457,311
2x1
64,776
Tatsl
EXPENDITURE ON
Ratslng ThJnd5
95,515
95.515
16,407
CHARITABLE AcnviTZES
Care and Support
Awareness Ralslng &
Research for a Cure
47.757
192,337
7,361
47,757
192.337
47,957
103,849
4,796
TOTAL
973
NEY INCOMEI(EXPENDrnJRE)
236,808
236008
118,117)
RECONCILIATI(bN OF FUNDS
Totsl Amds BrrAKJht Forword
44,847
13,100
57.947
TOTAL FUNDS CARRIED FORWARD
£281655
£294 755
19

2023
2022
FIXED AssffS
12
CURREpif ASSErs
Debtors
sh It B)nk ird In tr4rKI
13
1.791
831
DITORS: Amounts
f•lllng wlthln on• y••r
J4
(8,9WJI
(10,663)
MEf CllRREiif ASSErs
LIABILrnES
57,947
Nrr ASSETS
É57 947
FUNDS
Lknrestrlrted Fw
Restrlcted Funds
16
281.655
13,100
44,847
13.100
TOTAL FUNDS
The dwltsble Col￿nY L4 enll¥ed b) fmm urAler S•lb)n 477 of im Art 2006 for the
year ended 31 t>ecwrthr 2023.
The members the ccAnpJny ty ot￿n of Its fknarKI)I statw*rts for the yw ￿ded 31
Oecember 2023 In accorda￿ wth SeLkn 476 clthe P£t 200&
The trustees xkncw* thdr res*(￿s￿lt￿S for
lo) er6urlrrtJ that tPt tharlable clyroany keeps accMrthKI re£fmts that coriyPy ￿ Sedlcr6 386 and 387 of the
Companies Act 21)J6 and
(b) Preparlng flnanaal statements whKh gi￿ a true arml faSr ¥￿¥ of the state of the thadtabSe
crynpany as * the erKI of exh finaTr*l y&ir of Ws defhyt for eath Ibnandal y In accordarte
wlth the requirements of Sertknrn% 394 and 395 a￿1 whkh Otherw1￿ Clxn￿Y wlth the requ*ements ofthE
COrnpan￿ 20CA rel¥kn to statemerts. ￿ far as applcable to tr* d￿rttab￿ ccIn￿nY.
subjert to the small reglme.
The fin￿da1 statemerts apprnbYJJ ty the 8oanl CA Trusites and *th)rI￿ for 28 ¥anber 2024
and ￿tTe sha￿d on Rs behay ty:
T Akhada- Trustee

E HPV AND AN
2023
2022
Net incomel{e¥w)(fitU￿> for the reixytry
DepreC￿tIOn charge
Interest payable
Investrnent irKome
(Increaselldeuease kn debtows
InCrea￿(de￿eosel h crei1th5
{18,lJ7)
1250)
(960)
(1,683)
(22)
(504)
2,594
Net cash p￿ded byl(LwI in) operaVn9
INVESTING Acri￿
Investment Incc*ne
Purchase of equlpment
Net cash provloed byllused kn) SnI￿tir9 xtithies
FINANc￿G Acnvmes
Repayrnent of t¥Jrrowlr
Cash Inflow5 Irc￿ new
Cth flows from flnbndrrfj a¢lvlt6es
233,915
16,019
29)
22
Change In cuh and cash e4ulv•knts In th•
r¢ptsrtSng perfod
Cash •thd cash •qulv•knts •t the b•9innlng of th•
reportlng perlod
Cash and ¢ash equlv•l•nts at th• qnd of th•
234,165
(16.027)
67,779
83,806
301,944
67,779
21

ACCOUNTING pouaES
Basls of Pr•parntlon of Acwirts
The flroncial statements of the charitable compwry. *tiich Is a public ￿nefft entty wder FRS 101 have be
preparej in accordan￿ wrth the thartues SORP (FRS 1021 Accountyng arn1 Remiw ty Charibes: Statement of
Recommended prnCti￿ applicable to tharities pr￿rir￿ th￿r acajunts in aCCCfdar￿e wth ￿ ￿nantial Reporting
Standard aprAlcabk In the UK and Reput4ic of IrekTrJ IFRS 1021, FinarKial Rwt"n9 Stsndard 102'The Nnantial
RepoTbn9 Stsndard apFIKable In ￿ UK Rewblic d Ird*' and tr* cryan￿$ kt 20C6. fin0￿￿1
statements have teen prepared ￿ the hlsiorlcal tost tonvèntsn.
Golng Concern
trustees ¢ongd¥ tl4it thwe we urKortalnlJe5 aixThrt the Charws ablllty tts ¢(￿￿nue as a Wrij
Fln•Klal R•portlng Sl•nd•nl 102- rnthK•d dlsdosure exemptlons
The thariVJble company has taken advantrge ol the following disdosure exemptbjis in pryring these
Flnanclal ststen￿nts, as Fennltte(J by FRS 102 The Fkw¥JJl Wrtlr#J StJndaTd applicab￿ In the UK aTr
Rewbfic of Iretsnd,,
• The rejLIrer￿ of Se¢tlM 7 *aierr*rt Gl Htrrts.
Income
All Income Ls re￿￿n￿ed In ￿ &atement of P•Mes orKe the thèrbty has enOt5wnw* to fiJnds, It
Is prc*Jbte that tr* I￿orne wlli be recdved am￿nt can be meawred rtllabty.
Exp•ndltur•
LIabIl￿$ are recognw ès eKpwthtwe as as the￿ 15 a l* of constructive obllgatlon o)mmltUng the
dwrity to that exFenditure, it is probable t￿at a transfer of eCo￿rt tenefits wlll be required in setdement aN
the amojnt of the c+JlwJation can be measured rdhibty. Expendrture is afxounted ts on an awuaLs Iwgs and
been dasslfied under headlngs that a99re9tte al cc6t relatsj to the otegory. Where cannot be
dSr&*y a￿￿rted to partular headiNJs they been al￿ated to actNilie5 on a basls cor&stent with the u
of resour￿.
Grants ¢)ffered 9￿lect to cor￿n￿)n$ bthtch rYJt been met èt the year end date are rKJted as a commltment
but not accru8J as eXpend￿u￿.
Tangltsl• Flx•d Asmts
Deye¢KItKJn is provKled at the fi4bwng annual r*s to vfflte Lrff eath asset over its estimated usefvl
Ctean Ixat acce5%rn- 3 year&
T•xatlon
The chanty is ￿eMpt frcffi typorntion tsx dWrItab￿ acbvibe&
Fund Accounll
Unreslrlrted fuThts can be used In xc(ttlw wlh tts ttwltsble ¢OJ￿￿¥eS at the dxreuon ofthe trustee5.
Restrictgj fijnds can only be used for partialar rethLted purrthe within tl* Ltycts of the chw*y. Re￿rf¢tKIrS

THEA
AccouNfThG pouaES- ¢ontlnu•d
nd Aecountl
Further wlJnaWon of the nature aTh1 of th fu￿ is Ind￿ In the rKtss to the finanthl ststements.
The charrtat4e c(Ynpany Lwates a defmed contn.txrt￿n per￿n Contrkni rtlon5 payabfe to the
tharltaUe company's per&Kn scheme are tharged to ￿ strt￿n of F￿al￿al Actiwdes In the *rFod to whkh
they rdatr.
Judgements and K•y of Estlmatlon Uncert•lnty.
No judgen￿t (apart those invLYwng estirnaiesl have been In tre proces5 of apF4wry the ab)ve
accountthvJ OKie5 that hove s*Jth13nt dfert on amunts re(0gTh￿ in finarKlal Statem￿1.
GRApifs ANO DONATIONS
2023
2022
Grants
DonatkJn5 aryl glft akl
lo,(￿)
112,220
122 220
85,156
OThER TKAND114G ACIIVITIES
2023
2022
FLndratslrrfJ Ew)ts
457 311
RA151NG FUNDS
Ratslng Domtlons •nd Leg•d
2023
2022
Stsff Costs
D•ent Expenses
t)onor Software Subscrlpuon
Event ExFenses
5uppc*t Costs
6,58S
42
2,167
4,626
32
3,246
&3,139
2,108
23

E YEAR EN
CHARrrABLE ACTMTIES cosrs
Grnnt
Funding of Costs (Re
Actlvltl•s
note 7)
(see nrte 6)
2023
Tots
CarE and 9JFPNt
Awarentss Ralstrrfj & Ed￿￿on
Researth for a Cure
40,826
158.820
6,931
10,583
3,536
47,757
192,337
22,934
247 458
Support
ndlng of Corts (xe
A¢tlvttle5
note 7)
(M• not• 6)
2012
Totals
Carè SuHyort
Awareness Raisng &
Rewrch for a Cure
31,802
65.467
16,155
21,313
47,957
103,849
17,C69
156 602
GRAP￿5 PAYABLE
2023
2022
Awaren￿ Ra￿ing & EdLKatk
The totsl wants pakl to InstslutK￿s the yw was as
fdlrths
2023
2022
European Caw (tynis)tK)n
aobal Action on Men's Health
17,934
17,069
934

SIJPPORT cosrs
2023
2022
Bonk charyes
Pen51ons
Rent and r*s
Jnsuran
Fee5 and substhptk
301
410
4.984
5,724
276
7,212
3Cfj
828
741
400
7.658
Sundrles
Travel and meetlThJs
staff trainirvj
ConsiAtancy fees
cOnfere￿e expe￿e5
IndepeTrdent examlnalhy* fee
PLcwntsro and *1 fees
333
52
20,600
2,146
5,100
4,9BO
732
£42 159
NEf INCOME {EXPENDmiRE)
2023
2022
Net Ir￿n￿[Expe￿i*￿e) is stated after d￿rgIn￿{cre(lltJr1J).'
IrthFendent Examiw s Fee
£4 980 £5 100
TRumES' REMUNERATtON AND BEIIEFTts
There We￿ no tDJstees' remuneration LY other beMfits lor tre ￿Or ended 31 December 2023 w for I
year ended 31 Decemt* 2022.
There were Tr) tru5tees' expense5 pad the 31 C*cemiEr 2023 nor for the ended 31
Decemter 2022.
10. STAFF COSTS
2023
2022
Wages and Salarfe5
Sccial Seojrity Costs
Oth¥ PensK)n Costs
40,295
4,955
1.350
42.567
4,956
1,356
£46 600 £48 879

io.
STAFF COSTS- ￿ntInUed
2023
2022
A*rage monthly anpbyees
The key management personnel of ￿ d)arty a￿ those havirrfJ a￿th￿ty responslbility for
annlno, dlredlno (c￿￿11n0 the aetwitieg ol the dwrty. dlrecty or lThJifeLty, Ind¥Kllng any trLrstee of
the charty and, In the case of the tharlty, Indth tt* D￿rt¢rf of UK Operat*)ns. Totsl emp* b￿alts
paid to kw marw9emw)t ptrsomel in the Fentyj amounted to £45.250 (2022.. £47,523),
ii.
COMPARATIVES FOR TrIE sfATEMEpif OF FINANCTAL AcfivmES
Futhth
Funth
Tot•1 Fund#
INCOME AMD ENDOWMENTS FROM
Donathjrts Legades
90,094
other Tr>JlThJ ktivit*s
Investrnent IrK
64.776
64,776
Totsl
154
92
EXPENDITiIRE ON
Raising Funds
16.407
16.407
Char?table Activilierf
Qre and Supp)r(
AWa￿￿e$S Raising & Educati
Researd) a Cure
47,957
103.849
47,957
103,849
Tot•1
NET INCOMEI(EXPEMDrnIRE)
{18,117)
(18.117)
RECONCILIATION OF FUNDS
Total Brought Fon¥ard
13.ICKJ
76,064
TOTAL FUNDS CARRIED FORWARD

THE HPV AND ANAL CANCER FOUNDATION UMrrED
THEA
END
istD
BER
12.
TANGIBLE FIXED ASSErs
Plant and
Machinery
COST
At l January 2023 and
31 December 2023
DEPRECIATION
At l January 2023 arnl
31 December 2023
NET BOOK VALUE
At 31 DecernL￿r 2023
At 31 D￿ernber 2022
13.
DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023
2022
Gift Aid Re￿erable
831
14.
CREDITORS: AMOUNTS FALUNG DUE WrnIIN ONE YEAR
2023
2022
Deferr8J Income
Accrued Expenses
5,922
£10 663
27

AND ANAL
ccouKrs
DED 31
MBER 20
15.
ANALYSIS OF IIEf ASSEfs BEfwEEN FUNDS
Funds
Funds
2023
2022
Current Assets
Current Liabilities
272,675
13,ICK)
303,735
68,610
£281655
£13 ICQ £294 755
COMPARAIIVE
Funds
Funds
2022
2021
Current Assets
Current Lk?billties
55,510
13.100
68,610
84,133
£13 Its) £57 947
16.
MOVEMENT IN FUNDS
At
31.12.23
Brought Incom•
forward
Expendlture
Unrestrlcted Fund*
General FUTr
44,847
579,781
(342,973)
281,655
ReStrIct￿ Pundj
Researth for a Cure
13,100
13,100
TOTAL FUNDS
£579 781
£294 755
Net Movement In Funds, Ind￿ In the above are as f￿￿)w5.
Exp￿dIturn
At 31.12.22
forward
Unrestrl<*ed Funds
General Fund
62,964
154,892
(173,009)
44,847
Restrlcted Funds
Research for a Cure
13,1
13,1(Ki
TOTAL FUNDS
Capltal Fund
The HPV arKI Anal CarKer FOundat￿n Limtted has shareholder cakitsl equal to £1 and is owned by
HPV and Anal CarKer Foundathjn, a ￿lStered charity in the Unlted Ststes of America, EIN 27-3217520.
Research for a Cure Fund
The Fund was set up to award grants to research whKh wlll thn￿ devebwwit of efftttive fxeath)ents for
anal arKI all HpV-re1a￿ cancer5.

NDA
17. RELATED PARTY DISCLOSURES
No remunernthjn was to the tntstees in the ￿rI2022.. ENIL).
A numter oftrustees gave donatth to the Chty durfrg the year. There ¥¥ve r￿1 condltions attathed to
those dcfflaO￿s, The a)Jregate d￿311)n5 gl¥en to CN4rty by rdated parttes was £35.400.
18. GOING CONCERN
The Trustee5 have Cons1￿ the effect of the current eo)norric dlmte on tharitvs act1￿1125. Tr Charty
cufftndy IKJlits a comfortable of reseNes. aThJ ts l&ed costs are not 5b3nificant. It has tr* abilty to al￿n
its artlOlles to the thl of reserves avaiL7b￿. Tr Tru#ee5 are Wmistc abcxrt the fiJndrat5ir•J Quu￿k for tl
el￿ mcrth.